share_log

Ascendiant Capital Maintains Buy on PAVmed, Lowers Price Target to $21

Benzinga ·  Sep 10 17:31  · Ratings

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $22 to $21.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment